For bone-BM metastatic sites, the sensitivity of 123 I-MIBG and 18 F-FDG PET were 72.7% and 81.8%, respectively, and the specificity were 79.1% and 100%, respectively. 123 I-MIBG scan showed higher false positivity (20.8%) than 18 F-FDG PET (0%).
Introduction
Neuroblastoma (NBL) is the most common extracranial solid tumor in children 1) . It arises from embryonic neural crest cells derived from the peripheral sympathetic nervous system. Primary tumors can arise anywhere from the pelvis to the neck, and approximately 50% of patients present with distant metastasis to bone, bone marrow (BM), lymph node, and liver 2) . These clinical characteristics make assessment of the disease status dependent Korean J Pediatr 2014;57(6):278-286 on a multitude of studies.
Functional imaging with the catecholamine analogue 123 Imetaiodobenzylguanine ( 123 I-MIBG) has been widely used to assess tumors of the sympathetic nervous system since its development in the early 1980s 3) . 123 I-MIBG scan was well proved its high diagnostic accuracy for NBL assessment in the diagnosis, staging, treatment response and recurrence 4) . 123 I-MIBG scan showed high sensitivity and specificity in identifying metastatic involvement of the cortical bone, BM, and lymph nodes 5, 6) . However, 123 I-MIBG still has limitations in the interpretation of the normal distribution pattern in children 7) , and in the appearance of false-negative results 8) , which may lead to down-staging 9) . 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) has recently emerged as a promising functional imaging modality for various types of adult cancers, and is most frequently investigated in lymphomas, brain tumors and sarcomas. However, no sufficient studies have investigated the use of 18 F-FDG PET in NBL. Although 18 F-FDG PET showed tumor avidity for re vealing NBL in both soft tissue and skeletons, providing a good correlation with the disease status 10) , questions still remain regarding when and in which patients 18 F-FDG PET is most useful [11] [12] [13] . The purpose of the present study was to evaluate the potential utility of 
Materials and methods

Patients
We selected 8 patients with NBL diagnosed and treated at Ewha Womans University Mokdong Hospital between November 2005 and January 2013, who had residual mass due to incomplete tumor removal and who were able to simultaneously had both Tc-methylenediphosphonate (MDP) bone scans, computed tomography (CT) and/or magnetic resonance imaging (MRI), urine vanillymandelic acid, urine homovanillic acid, neuron specific enolase and BM examination.
The patients were treated with neo-adjuvant chemotherapy, surgery, 2 or 3 cycles of postoperative chemotherapy, high-dose chemotherapy and autologous stem cell transplantation according to our institutional protocol. Tc-MDP bone scan were also performed simultaneously. All imaging modalities were obtained within 14 days of each other after informed consent was obtained. F-FDG PET scans were preceded by a 6-hour period of fasting with water intake allowed. The dosage of 18 F-FDG was 5.18-7.12 MBq/kg with a maximum dosage of 440 MBq (10 mCi). Wholebody scans were performed using a PET/CT scanner 60 minutes after the infusion of 18 F-FDG. At first, CT scan was obtained, and transmission images were obtained after the emission scan. The images were reconstructed using filtered back-projection and iterative algorithm, and segmented attenuation and scatter correction was performed. A standardized uptake value (SUV), which is a quantitative measurement of tumor uptake of the 18 F-FDG adjusted for injected dose and body weight, was calculated for each lesion, and the maximum SUV of each lesion was determined from the image. F-FDG PET scans were analyzed by direct comparison on a patient basis as positive or negative, and recorded separately for the primary mass and bone/BM compartment instead of semiquantitative scoring systems for NBL 15) . On the 18 F-FDG PET scan, lesion was interpreted as positive lesion if lesion have focally increased 18 F-FDG uptake exceeding normal background uptake. During the routine follow-up, patients were followed by diagnostic CT or MRI of the abdomen or thorax every 6-12 months, and these morphological imaging were compared with the functional imaging for verification of the lesions. For the bone-BM lesion, BM examination by bilateral aspiration and biopsy at diagnosis and follow-up examinations and 
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'false-positive" or "true-negative" if it disappeared without any therapy during the follow-up period, or if lesion did not have viable tumor by histological verification. A lesion was classified as either "true-positive" or "false-negative" if it persisted or progressed during follow-up, or showed objective regression with therapy 13) .
Results
The clinical characteristics of the 8 patients are described in Table 1 . There were 3 males and 5 females and their median age at diagnosis was 3 years 6 months (range, 2 years 9 months to 5 years 6 months) and their INSS stages were; stage III in one and stage IV in seven cases. The primary tumor sites were; adrenal gland (n=5), posterior mediastinum (n=2), and organ of zuckerkandi (n=1). The patients had variable sizes of residual mass on the primary site after operation with range from about 1 cm to 6 cm in maximum diameter.
To define clinical significance of the residual tumor at the primary site and metastatic sites, a total of 45 combined 123 I-MIBG and 18 F-FDG PET scans were obtained from eight patients during the follow-up. The frequency of paired scan per patient were; six in patient 1, six in patient 2, seven in patient 3, four in patient 4, six in patient 5, four in patient 6, six in patient 7, and six in patient 8.
Detection of posttherapeutic residual tumor at the primary site
The patients had evidence of a residual primary tumor in the postoperative CT scans showing about an 1-to 6-cm range. All residual lesions were examined by CT, Table 2 ). The concordance between the both scans was observed 5 of 8 patients Table 2 ). The patient 3, who had a large residual abdominal mass (lesion diameter 4.5 cm×5.5 cm) was observed with positive uptake for 123 I-MIBG but a negative result in the 18 F-FDG PET scan (Fig. 1) . These falsenegative findings were repeatedly observed in 2 out of 7 followup scans. Finally, the negative avidity on the 18 F-FDG PET scan was false negative finding, which was confirmed as viable tumor by biopsy.
The I-MIBG negative lesion (Fig. 3) . The patient 2 who had a residual mass (adrenal gland, diameter 3 cm×4 cm) had been monitored regularly, and showed positive uptake in an Table 2 ). The concordance between the both scans was observed 6 of 8 patients (75%). Nevertheless, both Tc-MDP bone scan showed disseminated involvement of multiple skeletal uptake (Fig. 4) .
Detection of bone-BM involvement
Both modalities showed overall equivalence in detecting bone or BM metastasis; 18 were performed. And they showed that both modalities are relatively well-correlated with the disease status as determined by standard imaging modalities during follow-ups; overall concordance rates were 32/45 (71.1%) on primary tumor sites and 33/45 (73.3%) at bone-BM metastatic sites.
Many authors have been investigating to assess the potential utility of 18 F-FDG PET and 123 I-MIBG scans in children with NBL. So far, there are no conclusive reports to support which modality is more useful for monitoring the primary and metastatic lesions during follow-up.
123
I-MIBG scintigraphy has been widely used in clinical settings for the past 25 years in pediatric oncology providing high sensitivity and specificity in NBL. Nevertheless, it still has limitations in interpretation of unusual appearance of normal physiologic uptake such as upper thoracic and gastric region in children 7) , and leading to false-negative results 8, 9) . Moreover, there are some difficulties in detecting lesions during the follow-ups of NBL since 123 I-MIBG positivity on initial diagnosis may reverse negative avidity when the disease relapses 16) . Although presentation of false positive findings than These results implicated that 18 F-FDG PET might be better for detecting bone or BM metastasis than 123 I-MIBG scan. The bone scan did not precisely detect bone lesions, and it missed active bony lesion in 4 studies (8.8%) of patient 5. Data in all patients are summarized on Table 3 .
Discussion
In this retrospective study, we investigated whether . Shulkin et al. 11) reported that 123 I-MIBG scan was superior to 18 F-FDG PET, which showed lower tumor-to-nontumor uptake ratio and physiological F-FDG PET may be useful to clearly discriminate discrepancies, or inconclusive findings on the bone/BM metastatic NBL during follow-up. F-FDG PET in the assessment of disease extent in high-risk NBL 18, 19) . 123 I-MIBG was more sensitive for bone lesions than 18 F-FDG PET in patients of the NANT trial 18) . Consequently, it still remains difficult to predict the clinical roles and accuracy of 18 F-FDG PET scans in NBL. 123 I-MIBG is known to be highly sensitive and specific for identifying metastatic involvement of cortical bone and BM, and 18 F-FDG PET was better for identifying soft tissue lesions. However, our study showed conflicting results for identifying individual lesion in NBL. The discrepancy between the two modalities for detecting individual tumor lesions may be due to small sample size, preselected high-risk study populations, and variability of F-FDG. MIBG is an analog of the adrenergic norepinephrine neurotransmitter, which is taken by the adrenergic origin of NBL and pheochromocytoma using the type 1 cathecolamine uptake mechanism for transport into tumor cells 17) . Uptake of 123 I-MIBG was highly variable in vivo, and probably influenced by multiple factors such as degree of differentiation in neuroendocrine tumor, interfering medication, and change in the metabolism of the malignant cells due to altered biology 13, 20) . 18 F-FDG, similar to glucose, is transported to within the cells via the GULT (glucose transporters) and intracellular phosphorylated by hexokinase into glucose-6-phosphate and 18 F-FDG-6-phosphate. 18 F-FDG-6-phosphate entrapped, and steadily accumulates in metabolically active cells with different uptake mechanism with 123 I-MIBG 21) . Although most NBL and associated metastases have been shown to have good avidity for FDG, 18 F-FDG PET have shown variable results during/after treatment due to its lower tumorto-nontumor uptake ratio and FDG uptake in nontumor sites 4, 22) . 18 F-FDG PET also show false positive results in osteo-medullary assessment due to diffuse BM uptake after treatment (hyperactivity) with growth factors or radio-chemotherapy (rebound after treatment).
Another possibility for discrepant result is spontaneous regression or cellular differentiation of NBL tumor cells leading to false negative activity in 123 I-MIBG scan due to modification in the uptake mechanism, but we did not analyzed as a contributory factor in this study.
Our study showed both 123 I-MIBG and 18 F-FDG PET scans complement each other which is comparable to the recent study by Melzer et al. 13) . In their study, they showed the sensitivity values of 123 I-MIBG scintigraphy and 18 F-FDG PET to be 50% and 78%, respectively, and their specificity values to be 85.7% and 92%, respectively. They recommended 18 F-FDG PET as an additional modality when the results were discrepant or inconclusive with 123 I-MIBG, 18 F-FDG PET, and morphological imaging during the follow-up.
The limitations of this study is the small number of cases, which could have an influence in determining concordance or discordance rate, and the sensitivity or specificity. We recalculated the sensitivity and specificity from each patient to evaluate their effect. We finally confirmed that there was very little difference in values. Our study population to selective patients in the high risk NBL, who had residual tumors, and who were available for paired scans. The sensitivity and specificity of 123 I-MIBG scintigraphy is not applicable to the general population of NBL patients. This makes it difficult to compare our study results with the studies already published in the literature.
In conclusion, the functional studies, such as
